Originally described as a diagnostically useful marker for Ewing sarcoma, CD99 immunoreactivity has also been documented in a variety of other tumors, including hematopoietic neoplasms. By using conventional paraffin immunoperoxidase staining and tissue microarrays, we retrospectively investigated CD99 expression in a series of 160 anaplastic large cell lymphoma (ALCL) cases. Of the 160 cases, 103 (64.4%) were positive for CD99. The distribution of CD99 positivity was similar for nodal (66/103 [64.1%]), extranodal, (21/32 [66%]), and primary cutaneous lesions (16/25 [64%]). CD99 expression was present in 96 (64.4%) of 149 of the common type, 4 (80%) of 5 of the small cell variant, and 3 (50%) of 6 of the lymphohistiocytic variant cases. CD99 expression was slightly more frequent in anaplastic large cell lymphoma kinase (ALK)+ cases compared with ALK- cases (43/54 [80%] vs 44/81 [54%]). With 2 exceptions, ALK+ ALCL was seen only in patients younger than 41 years. We conclude that CD99 is frequently expressed in ALCL, with a slightly increased frequency in the younger age ALK+ cases. Nodal and extranodal ALCL should be considered in the differential diagnosis when a CD99+ neoplasm is encountered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1309/AJCPE68HZXCGWTKK | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas.
Clin Lymphoma Myeloma Leuk
December 2024
Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Electronic address:
Introduction: Histone deacetylase inhibitors (HDACi) and combination chemotherapy are independently used to treat relapsed/refractory (R/R) lymphoma. In vitro studies suggest that the addition of HDACi to platinum-based chemotherapy is synergistic.
Patients And Methods: We conducted a phase I study of romidepsin, gemcitabine, oxaliplatin and dexamethasone (Romi-GemOxD) in R/R aggressive lymphomas with an expansion cohort in T-cell lymphomas.
Case report: Therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective.
Front Pharmacol
December 2024
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Article Synopsis
- Driver mutations in tyrosine kinases like ALK are important in non-small cell lung cancer but uncommon in large cell neuroendocrine carcinoma (LCNEC).
- A 55-year-old woman with a history of breast cancer developed advanced LCNEC 10 years later, exhibiting multiple brain metastases and testing positive for the ALK fusion gene, leading to treatment with lorlatinib.
- The patient showed a significant tumor reduction after 6 weeks of lorlatinib therapy, indicating that ALK-positive advanced LCNEC might respond well to this treatment, especially for brain metastases.
Peri-Implant Enhancement of the Breast: Imaging Features, Significance, and Management Strategies.
J Breast Imaging
December 2024
Division of Plastic and Reconstructive Surgery, Mayo Clinic in Florida, Jacksonville, FL, USA.
Objective: Peri-implant enhancement can be seen on contrast-enhanced breast MRI, but its association with malignancy has not been described, leading to considerable variability in assessment and recommendations by radiologists. This study evaluated imaging features, management, and outcomes of implant-related enhancement.
Methods: This multisite IRB-approved retrospective review queried all breast MRI reports for keywords describing peri-implant enhancement, fluid, and/or masses (plus synonymous descriptions) and implant-associated malignancies, with subsequent imaging and chart review.
Rare giant epithelioid inflammatory myofibroblastic sarcoma of the abdominal cavity in a child: a case report and review of the literature.
Front Oncol
December 2024
Department of General Surgery, Xi'an Children's Hospital/Children's Hospital Affiliated to Xi'an Jiaotong University, Xi'an, China.
Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a distinct subtype of inflammatory myofibroblastoma tumor (IMT) that is recognized as a rare malignant tumor characterized by anaplastic lymphoma kinase (ALK) positivity, significant aggressiveness, treatment challenges, and a poor prognosis. We report on the case of an 8-year-old boy presenting with abdominal pain and vomiting. Computed tomography (CT) of the abdomen revealed a large tumor, and the pathology results following a biopsy confirmed the diagnosis of EIMS.
View Article and Find Full Text PDFEnhancement to effusion: Breast implant-associated anaplastic large cell lymphoma.
J Cardiol Cases
December 2024
Department of Internal Medicine, University of Texas at Austin Dell Medical School, Austin, TX, USA.
Unlabelled: This case is a rare presentation of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), where malignant pericardial effusion (MPE) served as the primary manifestation. A 58-year-old woman, post-breast implant removal, presented with pleuritic chest pain, fever, and chills. Clinical evaluation revealed jugular venous distention, muffled heart sounds, and hemodynamic instability.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!